Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Read more about Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Read more about Noninvasive detection of HER2 amplification with plasma DNA digital PCR.
Predictive biomarkers for bevacizumab: are we there yet? Read more about Predictive biomarkers for bevacizumab: are we there yet?
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Read more about Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Developing safety criteria for introducing new agents into neoadjuvant trials. Read more about Developing safety criteria for introducing new agents into neoadjuvant trials.
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Read more about Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Read more about Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Read more about Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Read more about LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.
A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Read more about A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.
